(STVN) Stevanato SpA - Ratings and Ratios

Stevanato Group S.p.A. is a global leader in the design, production, and distribution of advanced solutions for the biopharmaceutical and healthcare industries. With operations spanning Europe, the Middle East, Africa, North America, South America, and the Asia Pacific, the company serves a diverse range of clients, including pharmaceutical, biotechnology, diagnostics, and life sciences companies. Its product portfolio includes drug containment solutions such as pre-fillable syringes, cartridges, vials, and ampoules, as well as in-vitro diagnostic solutions and drug delivery systems like pen injectors, auto-injectors, and wearable injectors. Additionally, the company offers diagnostic laboratory consumables, analytical and regulatory support services, and a range of medical devices. Its engineering segment provides pharmaceutical visual inspection machines, glass forming machines, assembling and packaging machines, and after-sales services such as spare parts and maintenance. Stevanato Group also offers contract development and manufacturing services for drug delivery devices, catering to drug product, glass packaging, and fill-and-finish contract manufacturers. Founded in 1949 and headquartered in Piombino Dese, Italy, the company operates as a subsidiary of Stevanato Holding S.R.L. and is listed on the New York Stock Exchange (NYSE) under the ticker symbol STVN.

3-month forecast: Based on and , Stevanato Group S.p.A. (STVN) is expected to trade in a range-bound pattern. The stock is currently trading above its 20-day SMA (20.94) but below its 50-day (20.71) and 200-day (20.57) SMAs, indicating potential consolidation. The ATR of 1.17 suggests moderate volatility. With a forward P/E of 37.59 and a P/S ratio of 5.53, the market is pricing in future growth. The RoE of 8.39% reflects moderate profitability. Technical resistance is likely at the 50-day SMA, while support may hold around the 20-day SMA. Expect average daily volume to remain stable at 312,245 shares. The stock is likely to remain range-bound between 20.50 and 22.50 over the next three months, with potential for a breakout if earnings or macroeconomic conditions improve.